ESTRO 36 Abstract Book

S751 ESTRO 36 2017 _______________________________________________________________________________________________

H. Matsutani 1 , T. Shimbo 1 , H. Yoshioka 1 , N. Yoshikawa 1 , K. Yoshida 1 , M. Nakata 1 , T. Hamada 1 , T. Komori 1 , Y. Narumi 1 , Y. Uesugi 2 1 Osaka Medical College, Radiation Oncology, Osaka, Japan 2 Kansai University of Welfare Sciences, Medical treatment for health, Kashihara, Japan Purpose or Objective Goreisan （ TJ-17 ） is one of Japanese traditional Kampo medicine which is composed of five kinds of herbal medicines. TJ-17 has been found to suppress the abnormal water movement through the aquaporin inhibitory effect and an anti-inflammatory effect. Recently, TJ-17 has been indicated for cerebral edema and chronic subdural hematoma, and appears its effects soon. We have investigated whether the TJ-17 is effective in radiation enteritis. Material and Methods TJ-17 (7.5g/day) was administered 68 patients who received radiation therapy for the whole pelvis. The median age was 64 years old (range; 50-88). Fifty cases were male and eighteen cases were female. Sixty cases (92.6%) were combined chemotherapy (cisplatin and/or gemcitabine), eight cases received radiation alone. When patients showed the diarrhea grade 2 or more in the CTCAE v4.0, we administered TJ-17 without stopping radiation therapy. After prescription, we examined the number of defecation and stool property using a Bristol stool scale. Results All patients showed grade 2 or more diarrhea during radiation therapy. At the time of prescription, the median irradiation dose was 23Gy (range; 12-44). Before the administration, the median stool frequency was eight times (range; 4-20). Eighteen cases was type 6 (mushy stool), and fifteen cases was type 7 (watery) in the Bristol stool scale, the median scale was type 7 (average; 6.7). Bloody stools were observed in six cases. After one week administration of TJ- 17, fifty-three cases (77.9%) were improved the symptoms. In improved group, the median of decrease in the number of stool frequency was four times (range; 1- 19), and the median Bristol stool scale was type 6 (average; 5.4). Bloody stools were disappeared in three of 6 cases (50%). By using the Pearson product-moment correlation coefficient, from the appearance enteritis symptoms, it showed a correlation of moderate to start administering the TJ-17 earlier. Conclusion Japanese traditional Kampo medicines Goreisan (TJ-17) was effective against in acute radiation enteritis. EP-1421 Outcome by prognostic factors of AVM treated with LINAC:18 years experience, Spanish Institution S. Cafiero 1 1 Clinica de Occidente, Radiation Oncology, Santiago de Cali, Colombia Purpose or Objective Outcomes of cerebral arteriovenous malformations (cAVMs) treated with SRS by using LINAC, and results according to the Spetzler-Martin (SM) grading system and the Pollock-Flickinger (PF) score, in a series of patients (pts) from Onkologikoa in Spain Material and Methods 1995 to 2013, 320 pts with cAVMs treated with SRS by using a Clinac 21EX . Mean age 40 years ( 9-76), 61% men and 39% women. 57% of cAMVs in an eloquent area, 93% at the surface site (hemispheric/corpus callosum/cerebellar) and 7% at a deep site (basal ganglia/thalamus/ brainstem). Prior embolization in 36% of pts. A deep venous drainage was in 30% of cAVMs. The cAVM nidus volume PTV was divided into 3 groups: 0-2 cc (30.3%), 2.1

to 5 cc (31.6%), and > 5cc (32,5%). Mean margin dose 15 Gy ( 12-18 Gy) and the maximal 30 Gy Results PF Obliteration PF<1: complete 60% , partial 35%, no change 4.5%; PF 1.01-1.5: complete 43.5%, partial 47.5% , no change 9%; PF 1.51-2: complete 45%, partial 50%, no change 5%; PF > 2: 1.5% complete, partial 78.5%, no change 6.1%. Rebleeding PF <1: 2.4%; PF 1.01-1.5: 3%; PF 1.51-2: 3.8% and PF > 2 had no rebleeding, Toxicity PF <1: acute 13.5%, late 10,6% (clinical 4.7% radiological 3.5%, radiological and clinical 2.4%); PF 1.01-1.5: acute 16%, late 13% (clinical 8%, radiological 2%, clinical and radiological 3%); PF 1.51-2: acute 11.5%, late 12% (clinical 5%, radiological 3.5%, radiological and clinical 3.5%); PF > 2 : acute 17.5%, late 21% (clinical 18%, clinical and radiological toxicity 3%) SM Obliteration Grade I: complete 65%, partial 35%; Grade II: 50% complete, partial 45%, no change 5%; Grade III: complete 46% , partial 46% ,no change 8%; Grade IV : complete 17% , partial 72 % , no change 11%, and Grade V: any complete obliteration. Rebleeding Grade I: 5%, Grade II: 1,4%, Grade III: 3%, Grade IV: 13.%, Grade V no rebleeding. Toxicity Grade I: acute 12.5%, late 8.6% (clinical 4.3% , radiological 4.3%); Grade II: acute 3.7% , late 14% (clinical 7.5%, radiological 4%, radiological and clinical 2.5%); Grade III: acute 19.5 % , late 14%(clinical 4% radiological 3%, clinical and radiological 7%); Grado IV: acute 21%, late 29.5% (clinical 23.5 %, radiological and clinical 6%); Grade V: acute 100%, and no late Conclusion The experience of this single Institution are consistent with those published in the literature , low rate of rebleeding, acceptable toxicity, and obliteration rate that varies with the nidus size and the prognostic factors according to the (SM) and the (PF) EP-1422 Pregnancy outcomes in cancer patients received radiotherapy: a nationwide population-based study Y.J. Chiang 1 1 Chang Gung Memorial Hospital- Linkou, Department of Radiation Oncology, Taoyuan, Taiwan Purpose or Objective To estimate the risks of adverse maternal outcomes in female cancer patients received radiotherapy (RT) compared with women without malignancy. Material and Methods We identified 2,350,335 singleton pregnancy using Taiwan National Health Insurance Database and Taiwan Birth Registry between 2001 and 2012, of which 607 pregnancies were in female cancer patients with RT. Odds ratios (ORs) and 95% confidence intervals (CIs) for maternal outcomes were estimated using generalized estimating equation model adjusted by maternal age, Charlson comorbidity index, urbanization, income, occupation and birth of year. Results From 2001 to 2012, pregnancies in female cancer patients received radiotherapy were associated with an adjusted OR (95% CIs) of 1.46 (1.02-2.09) for severe postpartum hemorrhage compared with women without malignancy. Otherwise there were no significant increasing risks with an adjusted OR of 0.95 (0.84-1.07) for Caesarean section, 0.56 (0.39-0.80) for preterm labor, 0.84 (0.64-1.11) for antepartum hemorrhage, 0.48 (0.32-0.74) for pregnancy